Results 1 to 10 of about 545 (197)
Advances in Hematology, 2009 The development of adverse cardiovascular events despite aspirin use has established an interest in a possible resistance to the drug. Several definitions have been set and various laboratory testing modalities are available. This has led to a wide range
Khaled Mansour +3 more
doaj +9 more sources
Journal of Thrombosis and Haemostasis, 2005 Treatment failures occur with any drug and aspirin is no exception. Evidence is growing to indicate that there are subpopulations that do not respond to antithrombotic action of aspirin. The term 'aspirin resistance' has been used to describe a number of different phenomena, including inability of aspirin to: (i) protect against cardiovascular events ...
A, Szczeklik +3 more
exaly +7 more sources
British Journal of Surgery, 2002 OBJECTIVE: To review the literature addressing the problem of aspirin resistance in patients with vascular disease. DATA SOURCES: A MEDLINE search (1966–February 2002) was performed.
J, Smout, G, Stansby
+7 more sources
The prevalence and associated factors of aspirin resistance among prophylactic aspirin users [PDF]
Romanian Journal of Neurology, 2021 Background. Aspirin is an antiplatelet used for the secondary prevention after vascular events. It is also suggested for the primary prevention of vascular events in high risk people, however, despite using standard prophylactic doses, aspirin resistance
Samaneh Ghorbani-Shirkouhi +5 more
doaj +1 more source
Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia
Stroke Research and Treatment, 2021 Objective. To evaluate the aspirin resistance prevalence in patients with previous ischemic cerebrovascular disease undergoing aspirin therapy for secondary prevention. Materials and Methods.
Alejandro Roman-Gonzalez +12 more
doaj +1 more source
Frontiers in Pharmacology, 2020 Background and purposeAspirin is a novel anti-platelet drug that is intensively recommended for the prevention and treatment of cerebral ischemic stroke.
Jue Wang +8 more
doaj +1 more source
Aspirin and Clopidogrel Resistance [PDF]
Mayo Clinic Proceedings, 2006 Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays.
Erin D, Michos +4 more
openaire +2 more sources
Aspirin resistance: position paper of the Working Group on Aspirin Resistance [PDF]
Journal of Thrombosis and Haemostasis, 2005 Aspirin irreversibly acetylates serine 529 of cyclooxygenase (COX)-1, resulting in inhibition of thromboxane A2 generation by platelets and prostacyclin by endothelial cells [1]. Because platelets lack the synthetic machinery to generate significant amounts of new COX, aspirin-induced COX-1 inhibition lasts for the lifetime of the platelet. In contrast,
MICHELSON AD +10 more
openaire +5 more sources
Aspirin resistance in patients with acute coronary syndrome. Part 2
Кардиоваскулярная терапия и профилактика, 2011 Aim. In patients with acute coronary syndrome (ACS), to investigate the prevalence of aspirin resistance, its clinical features, prognostic effects, and potential correction. Material and methods.
N. S. Frolova +4 more
doaj +1 more source
Herz Kardiovaskuläre Erkrankungen, 2008 Recent clinical studies have shown that the expected antiplatelet effect of aspirin is not always achieved. From the laboratory point of view, resistance to aspirin is the inability to achieve the expected inhibition of platelet cyclooxygenase-(COX-)1 with prevention of platelet thromboxane (TX) A2 formation.
Norbert, Zimmermann +2 more
+7 more sources